Researchers at the National Institutes of Health developed a novel treatment using resiniferatoxin (RTX) to reduce severe, treatment-resistant cancer pain. In a first-in-human trial, patients experienced significant reductions in pain intensity and opioid use following a single injection of RTX into the cerebrospinal fluid. RTX selectively targets pain-transmitting neurons and may have potential in other challenging pain conditions.

Source: NEJM Evidence